Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer

Journal of Gastrointestinal Surgery

Volumn 6, Issue 2, 2002, Pages 159-166

  Hotz, Hubert G ^a,d   Gill, Parkash S ^c   Masood, Rizwan ^c   Hotz, Birgit ^a   Buhr, Heinz J ^b   Foitzik, Thomas ^b   Hines, O Joe ^a   Reber, Howard A ^a   Fernandez Del Castillo, C ^e   Neoptolemos, J ^e   Fink, V ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e NONE

Author keywords

Angiogenesis; Diphtheria toxin; Pancreatic cancer; Vascular endothelial growth factor

Indexed keywords

DIPHTHERIA TOXIN VASCULAR ENDOTHELIAL GROWTH FACTOR FUSION PROTEIN; HYBRID PROTEIN; PHOSPHATE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; DIPHTHERIA TOXIN; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ESCHERICHIA COLI; GROWTH INHIBITION; HEALTH CARE; HEALTH SERVICE; HUMAN; MALE; METASTASIS; MICROVASCULATURE; MOUSE; NONHUMAN; PANCREAS; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; STAINING; SURVIVAL; TARGET CELL; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; CELL DIVISION; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; FEMALE; NEOVASCULARIZATION (PATHOLOGY); NONPARAMETRIC TEST; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; PROBABILITY; RANDOMIZATION; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL DIVISION; DIPHTHERIA TOXIN; DISEASE MODELS, ANIMAL; ENDOTHELIAL GROWTH FACTORS; FEMALE; LYMPHOKINES; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PANCREAS; PANCREATIC NEOPLASMS; PROBABILITY; RANDOM ALLOCATION; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 19044367102     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(01)00040-3     Document Type: Article

References (34)

1. Parker SL, Long T, Bolen S, Wingo PA. Cancer statistics. CA Cancer J Clin 1997;47:5-27.
2. Warshaw AL, Fernandez del-Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-465.
3. Yeo CJ, Cameron JL. Pancreatic cancer. Cur Probl Surg 1999;36:59-152.
4. Trede M, Saeger HD, Schwall G, Rumstadt B. Resection of pancreatic cancer-surgical achievements. Langenbecks Arch Surg 1998;383:121-128.
5. Glimelius B. Chemotherapy in the treatment of cancer of the pancreas. J Hepatobiliary Pancreat Surg 1999;5:235-241.
6. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776-782.
7. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nature Med 1995;1:27-31.
8. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
9. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000;60:203-212.
10. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989-991.
11. Arora N, Masood R, Zheng T, Cai J, Smith L, Gill PS. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res 1999;59:183-188.
12. Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 1996;56:1324-1330.
13. Drazin R, Kandel J, Collier RJ. Structure and activity of diphtheria toxin. II. Attack by trypsin at a specific site within the intact toxin molecule. J Biol Chem 1971;246:1504-1510.
14. Collier RJ, Kandel J. Structure and activity of diphtheria toxin. I. Thiol dependent dissociation of a fraction of toxin into enzymatically active and inactive fragments. J Biol Chem 1971;246:1496-1503.
15. Wilson BA, Collier RJ. Diphtheria toxin and Pseudomonas aeruginosa exotoxin A: Active-site, structure and enzymatic mechanism. Curr Top Microbiol Immunol 1992;175:27-41.
16. Guan K, Dixon JE. Eukaryotic proteins expressed in Escherichia coli: An improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase. Anal Biochem 1991;192:262-267.
17. Tan MH, Shimano T, Chu TM. Differential localization of human pancreatic cancer-associated antigen and carcinoembryogenic antigen in homologous pancreatic tumoral xenograft. J Natl Cancer Inst 1981;67:563-566.
18. Metzgar RS, Gaillard MT, Levine SJ, Tuck FL, Bossen EH, Borowitz MJ. Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies. Cancer Res 1982;42:601-608.
19. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Meth 1983;65:55-63.
20. Hotz HG, Reber HA, Hotz B, Sanghavi PC, Yu T, Foitzik T, Buhr HJ, Hines OJ. Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth. J GASTROINTEST SURG 2001;5:131-138.
21. Hotz HG, Hines OJ, Foitzik T, Reber HA. Animal models of exocrine pancreatic cancer. Int J Colorect Dis 2000;15: 136-143.
22. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995;36:169-180.
23. Rosenberg L. Pancreatic cancer. A review of emerging therapies. Drugs 2000;59:1071-1089.
24. Brown JM, Giaccia AJ. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-1416.
25. Kuehn R, Lelkes PI, Bloechle C, Niendorf A, Izbicki JR. Angiogenesis, angiogenic growth factors, and cell adhesion molecules are upregulated in chronic pancreatic diseases: Angiogenesis in chronic pancreatitis and in pancreatic cancer. Pancreas 1999;18:96-103.
26. Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Bucchler MW, Korc M. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997;3:1309-1316.
27. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000; 88:2239-2245.
28. Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H, Miyake M. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 1999;79:1553-1563.
29. Niedergethmann M, Hildenbrand R, Wolf G, Verbeke CS, Richter A, Post S. Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection. Int J Pancreatol 2000;28:31-39.
30. von Marschall Z, Cramer T, Hocker M, Burde R, Plath T, Schirner M, Heidenreich R, Breier G, Riecken EO, Wiedenmann B, Rosewicz S. De novo expression of vascular endothelial growth factor in human pancreatic cancer: Evidence for an autocrine mitogenic loop. Gastroenterology 2000;119:1358-1372.
31. Wild R, Dhanabal M, Olson TA, Ramakrishnan S. Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: Differential effect on proliferating endothelial cells. Br J Cancer 2000;83:1077-1083.
32. Hotz HG, Hines OJ, Hotz B, Yu T, Buechler P, Reber HA. Anti-angiogenic therapy for pancreatic cancer: The effect of a neutralizing anti-VEGF antibody in-vitro and in-vivo. Pancreas 1999;19:424.
33. Hotz HG, Hines OJ, Reber HA, Foitzik T, Buhr HJ. Anti-angiogenic therapy with a neutralizing anti-VEGF antibody reduces tumor size and metastasis in an orthotopic model of pancreatic cancer. Chir Forum 2000;29:85-88.
34. Olson TA, Mohanraj D, Roy S, Ramakrishnan S. Targeting the tumor vasculature: Inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate. Int J Cancer 1997;73:865-870.